Redeye briefly comments on Isofol’s announcement that the German regulatory authority BfArM has approved an optimized design for the ongoing phase Ib/II study with arfolitixorin. We are encouraged by the addition of a control arm versus leucovorin, broadened inclusion criteria, and expansion to multiple study centers, which together should strengthen the clinical evidence package and support faster recruitment.
LÄS MER
